Detalhe da pesquisa
1.
Sequential CD7 CAR T-Cell Therapy and Allogeneic HSCT without GVHD Prophylaxis.
N Engl J Med
; 390(16): 1467-1480, 2024 Apr 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-38657244
2.
Relapsed/Refractory Peripheral T-Cell Lymphoma-Associated Hemophagocytic Lymphohistiocytosis With UNC13D and CD27 Germline Mutations.
Cell Transplant
; 33: 9636897231221887, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-38183241
3.
Safety and efficacy of autologous and allogeneic humanized CD19-targeted CAR-T cell therapy for patients with relapsed/refractory B-ALL.
J Immunother Cancer
; 11(2)2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36808074
4.
GPRC5D CAR T cells (OriCAR-017) in patients with relapsed or refractory multiple myeloma (POLARIS): a first-in-human, single-centre, single-arm, phase 1 trial.
Lancet Haematol
; 10(2): e107-e116, 2023 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-36725117
5.
Isolation, characterization and bioactivities of the polysaccharides from Dicliptera chinensis (L.) Juss.
Int J Biol Macromol
; 101: 603-611, 2017 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-28344090